.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A01A_StomatologicalPreparations.A01AB04_AmphotericinB.AmphotericinB .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A01A_StomatologicalPreparations.A01AB04_AmphotericinB.AmphotericinB| name: | AmphotericinB |
| ATC code: | A01AB04 | route: | intravenous |
| n-compartments | 2 |
Amphotericin B is a polyene antifungal agent primarily used for the treatment of serious systemic fungal infections, including aspergillosis, cryptococcosis, histoplasmosis, and candidiasis. It is generally reserved for severe cases due to its toxicity. Amphotericin B is approved for medical use and remains in clinical use, mainly as intravenous administration in hospital settings.
Pharmacokinetic parameters reported for adult patients with systemic fungal infections, following intravenous administration.
Groll, AH, et al., & Brüggemann, RJM (2019). Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 68(Suppl 4) S260–S274. DOI:10.1093/cid/ciz076 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31222253
Würthwein, G, et al., & Walsh, TJ (2005). Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrobial agents and chemotherapy 49(12) 5092–5098. DOI:10.1128/AAC.49.12.5092-5098.2005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16304177
Nath, CE, et al., & Earl, JW (2001). Population pharmacokinetics of amphotericin B in children with malignant diseases. British journal of clinical pharmacology 52(6) 671–680. DOI:10.1046/j.0306-5251.2001.01496.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/11736878